Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

With a trading volume of 7,459,075, the price of TEM is down by -4.37%, reaching $59.29. Current RSI values indicate that the stock is is currently neutral between overbought and oversold. Next ...

Tempus AI, Inc. TEM recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to ...

Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Tempus AI (TEM) recently secured FDA clearance for its Tempus ECG-Low EF software and expanded its collaboration with Personalis for colorectal cancer detection, measures that collectively ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

Tempus AI TEM and NVIDIA NVDA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing ...

Attorney Ron Sokol weighs the merits about cases going to trial, if there’s a choice, or settling out of court.

Activists with the pro-housing YIMBY movement have scored win after win at the California Legislature in recent years.

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...